Division of Medical Oncology, Department of Medicine, Dalhousie University and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
Human Health Therapeutics Research Centre, National Research Council of Canada, Halifax, Nova Scotia, Canada.
PLoS One. 2020 Aug 13;15(8):e0237308. doi: 10.1371/journal.pone.0237308. eCollection 2020.
The isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparative investigation between different analytic methodologies in clinically relevant settings. The objective of this study was to evaluate four different CTC isolation techniques-those that rely on surface antigen expression (EpCAM or CD45 using DynaBeads® or EasySep™ systems) or the biophysical properties (RosetteSep™ or ScreenCell®) of CTCs. These were evaluated using cultured cells in order to calculate isolation efficiency at various levels including; inter-assay and inter-operator variability, protocol complexity and turn-around time. All four techniques were adequate at levels above 100 cells/mL which is commonly used for the evaluation of new isolation techniques. Only the RosetteSep™ and ScreenCell® techniques were found to provide adequate sensitivity at a level of 10 cells/mL. These techniques were then applied to the isolation and analysis of circulating tumor cells blood drawn from metastatic breast cancer patients where CTCs were detected in 54% (15/28) of MBC patients using the RosetteSep™ and 75% (6/8) with ScreenCell®. Overall, the ScreenCell® method had better sensitivity.
循环肿瘤细胞(CTC)的分离和分析具有提供微创诊断、预后和预测信息的潜力。由于在临床相关环境中缺乏不同分析方法之间的比较研究,CTC 分析的广泛临床应用受到了阻碍。本研究的目的是评估四种不同的 CTC 分离技术——依赖于表面抗原表达(EpCAM 或 CD45 使用 DynaBeads®或 EasySep™系统)或 CTC 生物物理特性(RosetteSep™或 ScreenCell®)的技术。这些技术在培养细胞中进行了评估,以计算各种水平的分离效率,包括:实验间和实验员间的可变性、方案复杂性和周转时间。所有四种技术在 100 个细胞/mL 以上的水平上都足够有效,这是评估新的分离技术常用的水平。只有 RosetteSep™和 ScreenCell®技术在 10 个细胞/mL 的水平上被发现具有足够的灵敏度。然后将这些技术应用于从转移性乳腺癌患者采集的循环肿瘤细胞的分离和分析中,使用 RosetteSep™在 54%(15/28)的 MBC 患者中检测到 CTC,使用 ScreenCell®在 75%(6/8)的患者中检测到 CTC。总体而言,ScreenCell®方法的灵敏度更高。